Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Cytodyn Inc | Leronlimab with trifluridine plus tipiracil (TAS-102) and bevacizumab | CCR5+, microsatellite stable (MSS), relapsed or refractory metastatic colorectal cancer (mCRC) | Phase 2 | Trial Planned | Intravenous | Oncology |
| Cytokinetics Incorporated | Omecamtiv Mecarbil - (COMET-HF) | Heart Failure | Phase 3 | Enrollment Initiation | Oral | Cardiology |
| Cytokinetics Incorporated | Reldesemtiv (CK-2127107) - (FORTITUDE-ALS) | Amyotrophic lateral sclerosis (ALS) | Phase 2 | Oral | Neurology | |
| Cytokinetics Incorporated | Reldesemtiv (CK-2127107) | Chronic obstructive pulmonary disease (COPD) | Phase 2 | Trial Completed | Oral | Respiratory |
| Cytokinetics Incorporated | Aficamten - (FOREST-HCM) (OLE) | Non-obstructive hypertrophic cardiomyopathy (HCM) | Phase 2/3 | Data Released | Oral | Cardiology |
| Cytokinetics Incorporated | Aficamten - (REDWOOD-HCM) | Hypertrophic cardiomyopathy (HCM) | Phase 2 | Ongoing | Oral | Cardiology |
| CytomX Therapeutics Inc. | CX-2029 - (PROCLAIM) | Solid tumors / Diffuse large B-cell lymphoma (DLBCL), squamous non-small cell lung cancer (sqNSCLC), head and neck squamous cell carcinoma, and esophageal/gastro-esophageal junction (E/GEJ) cancer | Phase 2 | Looking for Funding | Intravenous | Oncology |
| CytomX Therapeutics Inc. | Praluzatamab ravtansine (CX-2009) | Breast cancer | Phase 2 | Trial Discontinued | Intravenous | Oncology |
